Department of Medicine and the College
Evgeny Izumchenko studies the complex interplay between the genetic and epigenetic alterations in carcinogenesis, with the aim of using this understanding to develop novel biomarkers for diagnosis and risk stratification, and to identify targets for therapeutic intervention. Specifically, he is interested in cancers of the upper aerodigestive tract and in defining the drivers underlying the premalignant progression. He partners with researchers and oncologists in academia and the pharmaceutical industry to advance discovery of biomarkers for early cancer detection and anticancer interventions.
His work on clonal evolution and heterogeneity provided proof of concept that genetic alterations associated with early neoplasms can be detected in bodily fluids. He identified several predictive biomarkers of a tumor’s response to therapy and defined metrics for patient stratification and prognostication. He also described novel mechanisms by which tumor cells evade death signals entrained by anticancer agents and the immune system, and by which dysregulation of genomic stability drives cancer development.
Izumchenko earned his PhD in molecular biology and immunology from Ben-Gurion University of the Negev, in Israel, where he also received his bachelor’s degree in laboratory medicine and master’s degree in clinical biochemistry. He completed his first postdoctoral training at the University of Florida, with a National Institutes of Health postdoctoral fellowship supporting his research. He completed a second postdoctoral fellowship at the Johns Hopkins University School of Medicine.